IPO

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against HireRight Holdings Corporation (HRT)

Retrieved on: 
Friday, April 26, 2024
HireRight, News, Risk, Suite, Employment, GPM, HRT, IPO, Defendant, Court, Alpha, Security (finance)

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

Key Points: 
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • On November 1, 2021, HireRight conducted its IPO, selling approximately 22 million shares of common stock at $19.00 per share.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • Glancy Prongay & Murray LLP, Los Angeles

New to The Street Announces Five Corporate Interviews, Televised Episode 570 Airs as Sponsored Programming on Bloomberg TV on Saturday, April 27, 2024, at 6:30 PM ET

Retrieved on: 
Friday, April 26, 2024
Dark, Money Maker, AI, Partnership, Privacy, Unicorn, Knowledge, COVID, Software, Communication, Entrepreneurship, General Atlantic, Real estate, AT&T, Uber, Artificial intelligence, Host, IPO, Perception, Student, Bloomberg Television, Internet, Interview, OTCQX, OTCQB, Data mining, BHG, PROMO, BHG Financial, Growth, FRA

Episode 570 airs as sponsored programming on Bloomberg TV on Saturday, April 27, 2024, at 6:30 PM ET.

Key Points: 
  • Episode 570 airs as sponsored programming on Bloomberg TV on Saturday, April 27, 2024, at 6:30 PM ET.
  • Albert started the Company in 2001 after seeing small businesses and entrepreneurs struggle to obtain capital to start and grow a business.
  • Traditional banks usually denied applications, or individuals would need to put up homes and other hard assets as collateral.
  • BHG can provide quick loans in as little as one day approval process with easy-to-understand payback provisions and terms.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against HireRight, and Doximity Innovations and Encourages Investors to Contact the Firm

Retrieved on: 
Friday, April 26, 2024
Prospectus, HireRight, COVID, News, Risk, Publication, Division of Tangney, Research, Complaint, Hold, Employment, Growth, HRT, Form, P.C, Risk management, IPO, Workforce, Register, Advertising, Organization, Alpha, Security (finance)

Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.

Key Points: 
  • Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.
  • That same day, pursuant to the Offering Documents, HireRight’s common stock began publicly trading on the New York Stock Exchange (“NYSE”) under the ticker symbol HRT.
  • At the time of the Complaint's filing, HireRight’s common stock continue to trade below the $19.00 per share IPO price.
  • For more information on the Doximity class action go to: https://bespc.com/cases/DOCS

HRT Class Action Notice: Robbins LLP Reminds Stockholders of the Lead Plaintiff Deadline in the HireRight Holdings Corp. Class Action

Retrieved on: 
Friday, April 26, 2024
IPO, HireRight, News, Risk, Publication, Hold, Employment, HRT, Risk management, Organization, SAN, Alpha, Security (finance)

The Allegations: Robbins LLP is Investigating the Allegations that HireRight Holdings Corp. (HRT) Filed Misleading Documents in Connection with its IPO

Key Points: 
  • The Allegations: Robbins LLP is Investigating the Allegations that HireRight Holdings Corp. (HRT) Filed Misleading Documents in Connection with its IPO
    On November 1, 2021, HireRight began publicly trading on the NYSE under the ticker symbol HRT.
  • The complaint alleges that the Offering Documents in support of the IPO were negligently prepared.
  • What Now: You may be eligible to participate in the class action against HireRight Holdings Corp. Shareholders who want to serve as lead plaintiff for the class must file their papers with the court by June 3, 2024.
  • A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Ventyx Biosciences, Inc. (VTYX)

Retrieved on: 
Thursday, April 25, 2024
News, Suite, GPM, IPO, Defendant, Court, Psoriasis

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

Key Points: 
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • On or about October 21, 2021, Ventyx conducted its IPO, selling over 9 million shares of common stock at $16.00 per share.
  • Then, on November 22, 2023, Ventyx disclosed that the Company’s President and Chief Medical Officer would no longer serve in those roles.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.

ROSEN, A LEADING LAW FIRM, Encourages HireRight Holdings Corporation Investors to Secure Counsel in Securities Class Action – HRT

Retrieved on: 
Thursday, April 25, 2024
Titan, Prospectus, HireRight, Risk, Advertising, Employment, HRT, IPO, Court

WHAT TO DO NEXT: To join the HireRight class action, go to https://rosenlegal.com/submit-form/?case_id=23874 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the HireRight class action, go to https://rosenlegal.com/submit-form/?case_id=23874 or call Phillip Kim, Esq.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

Reliance, Inc. Reports First Quarter 2024 Financial Results

Retrieved on: 
Thursday, April 25, 2024
CHIPS, Internet, International, Investment, Geography, Safety, CHIPS and Science Act, Hand, Webcast, Carbon, Growth, Public expenditure, Environment, IPO, PVQ, Pressure, Acquisition, ID, Government, Telephone, Renewable energy

SCOTTSDALE, Ariz., April 25, 2024 (GLOBE NEWSWIRE) -- Reliance, Inc. (NYSE: RS) today reported its financial results for the first quarter ended March 31, 2024.

Key Points: 
  • Reliance anticipates that demand for its products across the broader manufacturing sector will remain relatively stable in the second quarter of 2024.
  • Accordingly, the Company estimates its tons sold will be up 2.5% to 4.5% in the second quarter of 2024 compared to the first quarter of 2024, with approximately 2% of the sequential growth coming from recently completed acquisitions on April 1, 2024.
  • In addition, Reliance expects its average selling price per ton sold for the second quarter of 2024 to be down 1% to 3% compared to the first quarter of 2024.
  • A conference call and simultaneous webcast to discuss Reliance’s first quarter 2024 financial results and business outlook will be held on Thursday, April 25, 2024 at 11:00 a.m. Eastern Time / 8:00 a.m. Pacific Time.

DEADLINE ALERT for HRT, CKPT, and SOND: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

Retrieved on: 
Thursday, April 25, 2024
FDA, HireRight, Investment, Risk, Suite, Annual report, ROU, Employment, IPO, Law, Defendant, BLA, Bank statement, Security (finance)

LOS ANGELES, April 25, 2024 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.

Key Points: 
  • LOS ANGELES, April 25, 2024 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.
  • Investors have until the deadlines listed below to file a lead plaintiff motion.
  • Investors suffering losses on their investments are encouraged to contact The Law Offices of Frank R. Cruz to discuss their legal rights in these class actions at 310-914-5007 or by email to [email protected] .
  • The Law Offices of Frank R. Cruz, Los Angeles

Nucleome Therapeutics appoints Dr John Davis as Non-Executive Director of the Board and establishes Scientific Advisory Board of world-leading experts

Retrieved on: 
Thursday, April 25, 2024
Genetics, CMO, Doctor of Philosophy, Boston, Development, Novartis, Pfizer, Operating partner, Functional genomics, CSO, Genome, Associate, Drug discovery, SAB, AbbVie, Baxalta, EVP, GSK plc, Bristol Myers Squibb, GSK, Baylor College of Medicine, University, Harvard Medical School, Therapy, Biotechnology, Inflammation, Hospital, NIH, Michigan State University, Respiratory Medicine, Imperial College London, IPO, Rockefeller University, Spatial, MPH, Genomics, Atlas Venture, Merck Serono, Genentech, University of Birmingham, Senior, Society, Acquisition, Discovery, Sanofi, Baylor University

New Non-Executive Director of the Board, John Davis MD, MPH, MS, brings extensive and varied experience as a physician-scientist, drug developer and biotechnology executive.

Key Points: 
  • New Non-Executive Director of the Board, John Davis MD, MPH, MS, brings extensive and varied experience as a physician-scientist, drug developer and biotechnology executive.
  • The SAB is chaired by Prof. Jim Hughes, Scientific Founder and Non-Executive Director of Nucleome Therapeutics.
  • Dr Russell Greig, Non-Executive Chair of the Nucleome’s Board, said: “We are delighted to have appointed such esteemed experts to the Nucleome team.
  • Steve’s multifaceted background, spanning academia, industry and leadership roles, positions him as a key contributor to Nucleome’s Scientific Advisory Board.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of AXT, Inc. - AXTI

Retrieved on: 
Wednesday, April 24, 2024
Prospectus, IP, LLP, Prior, News, Pomerantz, IPO, AXT

NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of AXT, Inc. (“AXT” or the “Company”) (NASDAQ: AXTI).

Key Points: 
  • NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of AXT, Inc. (“AXT” or the “Company”) (NASDAQ: AXTI).
  • The investigation concerns whether AXT and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.
  • The Firm has recovered billions of dollars in damages awards on behalf of class members.